ORKA Reports Promising Phase 1 Results with Significant Skin Clearance
Oruka Therapeutics reported strong efficacy for its ORKA-001 treatment, achieving 63.5% complete skin clearance among participants, with favorable safety data. The stock surged 39% as analysts raised price targets, highlighting a competitive edge in psoriasis treatments with a potential for annual dosing.
View signal analysis